The estimated Net Worth of Andrew Lo is at least $1.35 Million dollars as of 29 December 2021. Andrew Lo owns over 7,500 units of BridgeBio Pharma Inc stock worth over $1,346,291 and over the last 7 years he sold BBIO stock worth over $0. In addition, he makes $0 as Independent Director at BridgeBio Pharma Inc.
Andrew has made over 19 trades of the BridgeBio Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 7,500 units of BBIO stock worth $98,850 on 29 December 2021.
The largest trade he's ever made was buying 14,285,714 units of BridgeBio Pharma Inc stock on 5 June 2018 worth over $25,000,000. On average, Andrew trades about 2,136,512 units every 43 days since 2017. As of 29 December 2021 he still owns at least 48,099 units of BridgeBio Pharma Inc stock.
You can see the complete history of Andrew Lo stock trades at the bottom of the page.
Dr. Andrew Lo serves as Independent Director of the Company. He is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of the MIT Laboratory for Financial Engineering, a principal investigator at the MIT Computer Science and Artificial Intelligence Laboratory, and an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science, and has served as a professor at the MIT Sloan School of Management and MIT Department of Electrical Engineering and Computer Science since 1988. He is also an external faculty member of the Santa Fe Institute and a research associate of the National Bureau of Economic Research. Dr. Lo currently serves on the board of directors of Roivant Sciences, Inc., a clinical-stage biopharmaceutical company. Dr. Lo holds a BA in Economics from Yale University and a Ph.D. in Economics from Harvard University.
Andrew Lo is 60, he's been the Independent Director of BridgeBio Pharma Inc since 2020. There are 8 older and 13 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
Andrew's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over $409,396,563 worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth $209,241,115 . The most active insiders traders include Global Investors Lp Viking ..., Andrew Lo, and Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,173,197. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth $1,554,481.
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include: